Free Newsletter
Dutch pull Pfizer infant vaccine after deaths
Dutch health authorities have yanked a batch of Pfizer's Prevnar following the deaths of three infants.
Prevnar, which is known as Prevenar in Europe, is used to protect infants from certain pneumococcal bacteria that can cause meningitis and bacteremia. Pfizer acquired the drug through its recent acquisition of Wyeth.
"On average about 5 to 10 deaths are reported annually after babies get vaccines," said a spokeswoman for the Dutch health institute RIVM. Each infant had received the vaccine within the past two weeks, according to Forbes.
Pfizer spokeswoman Gwen Fisher said preliminary investigations by the company and health authorities had found no link between the vaccinations and the deaths. Fisher said the company initiated the "quarantine" of the batch, which she said contained 110,000 doses of the vaccine. She added that the three infants also received two unrelated other vaccines as part of routine immunizations.
Read the Forbes story
Related Articles:
Fewer Prevnar doses work fine, study shows
Wyeth to up vax production in pandemic
Wyeth seeks FDA approval to market Prevnar 13
Vaccine proves widely effective against meningitis
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: